LDL-C lowering therapies are the backbone of CAD therapy, and their impact on the plaque milieu can vary, as described above. Still, they generally trend toward reduced vulnerable plaque volume and increased calcification and fibrous cap development, particularly for statins, ezetimibe, and PCSK9 inhibitors.
